Li Jun, Tumanut Christine, Gavigan Julie-Ann, Huang Waan-Jeng, Hampton Eric N, Tumanut Rachelle, Suen Ka Fai, Trauger John W, Spraggon Glen, Lesley Scott A, Liau Gene, Yowe David, Harris Jennifer L
Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, U.S.A.
Biochem J. 2007 Sep 1;406(2):203-7. doi: 10.1042/BJ20070664.
PCSK9 (proprotein convertase subtilisin/kexin 9) is a secreted serine protease that regulates cholesterol homoeostasis by inducing post-translational degradation of hepatic LDL-R [LDL (low-density lipoprotein) receptor]. Intramolecular autocatalytic processing of the PCSK9 zymogen in the endoplasmic reticulum results in a tightly associated complex between the prodomain and the catalytic domain. Although the autocatalytic processing event is required for proper secretion of PCSK9, the requirement of proteolytic activity in the regulation of LDL-R is currently unknown. Co-expression of the prodomain and the catalytic domain in trans allowed for production of a catalytically inactive secreted form of PCSK9. This catalytically inactive PCSK9 was characterized and shown to be functionally equivalent to the wild-type protein in lowering cellular LDL uptake and LDL-R levels. These findings suggest that, apart from autocatalytic processing, the protease activity of PCSK9 is not necessary for LDL-R regulation.
前蛋白转化酶枯草溶菌素/kexin 9(PCSK9)是一种分泌型丝氨酸蛋白酶,它通过诱导肝脏低密度脂蛋白受体(LDL-R)的翻译后降解来调节胆固醇稳态。PCSK9酶原在内质网中的分子内自催化加工导致前结构域和催化结构域之间形成紧密结合的复合物。虽然自催化加工事件是PCSK9正常分泌所必需的,但目前尚不清楚蛋白水解活性在LDL-R调节中的必要性。前结构域和催化结构域的反式共表达使得能够产生一种催化无活性的分泌型PCSK9。对这种催化无活性的PCSK9进行了表征,结果表明它在降低细胞LDL摄取和LDL-R水平方面与野生型蛋白功能等效。这些发现表明,除了自催化加工外,PCSK9的蛋白酶活性对于LDL-R调节并非必需。